Sigalov A
Drug Discov Today. 2020; 25(8):1298-1306.
PMID: 32405248
PMC: 7217646.
DOI: 10.1016/j.drudis.2020.05.005.
Martin-Blanco N, Blanco R, Alda-Catalinas C, Bovolenta E, Oeste C, Palmer E
Nat Commun. 2018; 9(1):2618.
PMID: 29976994
PMC: 6033938.
DOI: 10.1038/s41467-018-05050-6.
Perica K, Kosmides A, Schneck J
Biochim Biophys Acta. 2014; 1853(4):781-90.
PMID: 25200637
PMC: 4344884.
DOI: 10.1016/j.bbamcr.2014.09.001.
Castro M, van Santen H, Ferez M, Alarcon B, Lythe G, Molina-Paris C
Front Immunol. 2014; 5:132.
PMID: 24817867
PMC: 4012210.
DOI: 10.3389/fimmu.2014.00132.
Gong Y, Wang Z, Liang Z, Duan H, Ouyang L, Yu Q
PLoS One. 2012; 7(10):e47435.
PMID: 23077616
PMC: 3471819.
DOI: 10.1371/journal.pone.0047435.
Antigen-specific therapeutic approaches in Type 1 diabetes.
Clemente-Casares X, Tsai S, Huang C, Santamaria P
Cold Spring Harb Perspect Med. 2012; 2(2):a007773.
PMID: 22355799
PMC: 3281592.
DOI: 10.1101/cshperspect.a007773.
In vivo priming of IL-17(+) uveitogenic T cells is enhanced by Toll ligand receptor (TLR)2 and TLR4 agonists via γδ T cell activation.
Zuo A, Liang D, Shao H, Born W, Kaplan H, Sun D
Mol Immunol. 2012; 50(3):125-33.
PMID: 22301006
PMC: 3288362.
DOI: 10.1016/j.molimm.2011.12.013.
MHC class I dimer formation by alteration of the cellular redox environment and induction of apoptosis.
Makhadiyeva D, Lam L, Moatari M, Vallance J, Zheng Y, Campbell E
Immunology. 2011; 135(2):133-9.
PMID: 22044191
PMC: 3277715.
DOI: 10.1111/j.1365-2567.2011.03518.x.
The SCHOOL of nature: I. Transmembrane signaling.
Sigalov A
Self Nonself. 2011; 1(1):4-39.
PMID: 21559175
PMC: 3091606.
DOI: 10.4161/self.1.1.10832.
Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?.
Clemente-Casares X, Tsai S, Yang Y, Santamaria P
J Mol Med (Berl). 2011; 89(8):733-42.
PMID: 21499734
DOI: 10.1007/s00109-011-0757-z.
Dimeric MHC-peptides inserted into an immunoglobulin scaffold as new immunotherapeutic agents.
Goldberg B, Bona C
J Cell Mol Med. 2011; 15(9):1822-32.
PMID: 21435177
PMC: 3918039.
DOI: 10.1111/j.1582-4934.2011.01319.x.
Early T-cell activation biophysics.
Henry N, Hivroz C
HFSP J. 2010; 3(6):401-11.
PMID: 20514131
PMC: 2839812.
DOI: 10.2976/1.3254098.
Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity.
Ma Z, Sharp K, Janmey P, Finkel T
PLoS Biol. 2008; 6(2):e43.
PMID: 18303949
PMC: 2253636.
DOI: 10.1371/journal.pbio.0060043.
Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response.
Schamel W, Arechaga I, Risueno R, van Santen H, Cabezas P, Risco C
J Exp Med. 2005; 202(4):493-503.
PMID: 16087711
PMC: 2212847.
DOI: 10.1084/jem.20042155.
Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.
Ge Q, Stone J, Thompson M, Cochran J, Rushe M, Eisen H
Proc Natl Acad Sci U S A. 2002; 99(21):13729-34.
PMID: 12374859
PMC: 129758.
DOI: 10.1073/pnas.212515299.
Class I negative CD8 T cells reveal the confounding role of peptide-transfer onto CD8 T cells stimulated with soluble H2-Kb molecules.
Schott E, Bertho N, Ge Q, Maurice M, Ploegh H
Proc Natl Acad Sci U S A. 2002; 99(21):13735-40.
PMID: 12374858
PMC: 129760.
DOI: 10.1073/pnas.212515399.
Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes.
Savage P, Cowburn P, Clayton A, Man S, McMichael A, Lemoine N
Br J Cancer. 2002; 86(8):1336-42.
PMID: 11953895
PMC: 2375334.
DOI: 10.1038/sj.bjc.6600223.
T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model.
Stone J, Cochran J, Stern L
Biophys J. 2001; 81(5):2547-57.
PMID: 11606269
PMC: 1301723.
DOI: 10.1016/S0006-3495(01)75899-7.
Induction of T cell anergy by liposomes with incorporated major histocompatibility complex (MHC) II/peptide complexes.
van Rensen A, Taams L, Grosfeld-Stulemeyer M, van Eden W, Crommelin D, Wauben M
Pharm Res. 2000; 17(6):720-6.
PMID: 10955847
DOI: 10.1023/a:1007586400631.
Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers.
Daniels M, Jameson S
J Exp Med. 2000; 191(2):335-46.
PMID: 10637277
PMC: 2195759.
DOI: 10.1084/jem.191.2.335.